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The sexual dysfunctions are one of the most prevalent conditions. Sexual dysfunctions can have profound effect on the psychological
well-being of an individual and the psychosexual relationship of a couple. Management of the sexual dysfunction should be preceded
by an accurate diagnosis reached after a complete medical and sexual history and physical examination. Current focus of researchers
has been on understanding the pathophysiology of erectile dysfunction, premature ejaculation and other sexual dysfunctions that can
help in developing newer pharmacological cures for these conditions.
Recently, a number of clinical trials have studied the potential effectiveness of the phosphodiesterase (PDE)-5 inhibitor sildenafil in the
treatment of Erectile Dysfunction (ED) and Premature Ejaculation (PME). The introduction of PDE-5 inhibitors like sildenafil, vardenafil
and tadalafil has revolutionized the treatment of sexual dysfunctions.
This review focuses on the recent pharmacological advances in the treatment of common sexual dysfunctions like ED and PME with
special focus on the role of PDE-5 inhibitors. Also discussed is the pharmacological treatment of other less prevalent and recognized
disorders like female sexual dysfunction, drug induced sexual dysfunction etc.
Key words: Erectile dysfunction, premature ejaculation, sildenafil, PDE-5 inhibitors, sexual dysfunction.
Introduction
Satisfactory sex life is an important influencing factor for a
harmonious marriage. Sexual dysfunction deeply affects
personal life by causing isolation, frustration and decreased
self-esteem, which may extend into their job performance
and interaction with others. Despite the pervasiveness of
this problem, not until two decades ago were sexual
dysfunctions clearly defined and clinically evaluated.
Management of sexual dysfunctions should be preceded
by an accurate diagnosis after a complete medical and
sexual history and physical examination. It is also important
to quantify the magnitude of the problem as much as
possible. It is also important to determine the expectations
of the patient and his partner regarding the frequency and
the duration of the sexual act. A careful psychological
evaluation is also indicated to determine if a concomitant
psychosexual issue exists.
The pharmacological treatment of Erectile Dysfunction
(ED) has taken central importance amongst therapeutic
approaches for this increasingly recognized and widely
prevalent disorder. Although the pharmacological treatment
of Premature Ejaculation (PME) includes a wide array of
drugs like topical anaesthetic agents, antipsychotics, a-
adrenoceptor antagonists, tricyclic antidepressants and
selective serotonin reuptake inhibitors (SSRIs), an approved
treatment does not exist. Besides their success in treatment
of ED, phosphodiesterase (PDE)-5 inhibitors have also been
evaluated in a few clinical trials to investigate their efficacy
in treatment of PME.
This review highlights the pharmacological treatment of
various sexual dysfunctions primarily ED and PME. The
review also highlights the rationale between the use of PDE-
5 inhibitors and other agents in the treatment of sexual
dysfunctions, presents data from the clinical trials of agents
used in these conditions, and looks at the current knowledge




Definition: Erectile dysfunction (ED), a more precise term
for impotence, has been defined as the persistent or repeated
inability for at least 3 months to attain and/or maintain an
erection sufficient for satisfactory sexual performance
(Rosen et al., 1998; NIH Consensus Development Panel
on Impotence, 1993).
Since erection is a vascular event, an intact endothelium is
necessary for erection. The regulation of penile tumescence
inside the corpus cavernosum (CC) involves the balance
between contracting and relaxing factors, which regulate
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the functional state of smooth muscle cells. In the last few
years, the pathophysiological mechanisms of erection have
been partially clarified, and the molecular machinery of the
cellular components of the corpus cavernosum (CC) has
been widely investigated (Aversa et al., 2004). Recent
studies have highlighted the importance of local factors (i.e.
phosphodiesterases, rho-kinases and endothelins) and that
most pharmacological agents modulate the function of these
mediators of erection (Chitaley et al., 2001).
Various studies have shown that ED can have multiple
etiologies including organic, psychogenic and a combination
of both. Amongst organic causes neurogenic, arterial,
endocrinologic and cavernosal causes are prominent (Krane
et al., 1989; Burnett, 1998; Lue, 1995). Psychogenic causes
may include anxiety, depression, religious inhibitions,
‘widower syndrome’ and sexual phobias (Seftel et al., 2004).
Aging  (Althof & Seftel, 1995), drugs (Rosen et al., 1998)
and systemic diseases (Lue, 1992; 1995) may also cause
ED. Nocturnal penile tumescence monitoring is one of the
most effective methods to differentiate between organic
and psychological cause of ED.
Researchers in the last decade or so have tried to find a
pharmacological agent that fulfills the criteria of a first line
therapy for ED. A first line therapy for ED is one which is
easy to administer, reversible, non-invasive, low risk and
which is appropriate for a broad range of patients (Padma-
Nathan,  1999).
A) Oral Erectogenic Agents
Oral therapy with vasoactive agents has emerged as the
first line treatment and has transformed the manner in which
the general public views erectile dysfunction and even the
way health care professionals deliver care.
(i) Efficacy of PDE (Phosphodiesterase) -5 inhibitors
in ED
Sildenafil citrate is the first oral PDE-5 inhibitor approved
by the FDA for treatment of ED. PDE-5 inhibitors are
competitive and selective inhibitors of cGMP specific
phosphodisterase type 5, thus, inhibiting cGMP hydrolysis
(Sadovsky et al., 2001).
On sexual stimulation (CNS or sensory), the non-adrenergic
non-cholinergic neurons (NANC) produce nitric oxide (NO).
This nitric oxide activates guanylate cyclase in the vascular
smooth muscle cells increasing the synthesis of cGMP,
which in turn leads to smooth muscle relaxation. This leads
to the dilatation of the helicine arterioles allowing the
relaxation of the trabecular smooth muscles of corpus
cavernosum (CC) thus leading to inflow of arterial blood.
The increased blood oxygen tension in CC (from 25-40 ➞
90-100 mm of Hg) as well as the shear effect contributes
to endothelial nitric oxide synthase production, which further
increases the cGMP (Nehra et al., 2001). The PDE-5
inhibitor sildenafil increases the cGMP by inhibiting its
hydrolysis.
Short-term efficacy trials: Results in all the 21 placebo
controlled, flexible dose-escalation studies done so far
showed that PDE-5 inhibitor sildenafil produced greater
improvement in erectile functioning than placebo when
evaluated on International Index of Erectile Function (IIEF)
regardless of the cause, baseline severity and age of the
patients (Levine, 2000). In all the 2nd and 3rd phase trials,
sildenafil was found to be safe and well tolerated. The overall
discontinuation rates caused by adverse events were low
and statistically non-significant when compared to placebo
(Levine, 2000). All the side effects at 50-100 mg dose were
mild to moderate and related to the vasodilatory property
of sildenafil.
Long-term efficacy trials: The earliest open label, long-
term trial (1 year) found 88% of patient of ED to show
significant improvement (Guiliano et al., 1997). Subsequently
two long-term (2 years) randomized double blind, placebo-
controlled trials of sildenafil found that it had good safety
and tolerability; incidence rates of severe CVS side-effects
were comparable for patients receiving sildenafil or placebo
(Hackett & Gingell, 1999; Padma-Nathan et al., 1998). Post
FDA approval field experience update in Nov 1998 showed
efficacy rates similar to those in short and long-term trials.
Of the 128 deaths reported, 70% had one or more risk
factors for cerebrovascular disease and none of the deaths
were attributed to sildenafil alone (Viagra monologue,1999).
Three retrospective studies of patients of ED with comorbid
cardiac disorders have suggested that the incidence of
myocardial infarction / unstable angina in PDE-5 inhibitor,
sildenafil and placebo group was comparable (Conti et al.,
1999; Jackson et al., 1999; Herrmann et al., 2000). In a
meta-analysis on tolerability of sildenafil, Kloner and his
co-workers (Kloner & Jarow, 1999; Kloner et al., 2001)
found incidence rates of myocardial infarction (MI) to be
1.7 and 1.4 per 100 patient years with treatment in sildenafil
and placebo group respectively. Other side effects include
headache, hot flushes (Moreira et al., 2000; Morales et al.,
1998) blue green-colour vision (Wallis et al., 1998) and
premature acrosomal reaction leading on to failed
fertilization (Cuadra et al., 2000; Burger et al., 2000). Most
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researchers suggest that sildenafil is contraindicated in
patients using organic nitrates and can lead to fall in BP of
greater than 30 mm of Hg if taken within 24 hours of each
other (Webb et al., 2000). Important drug interactions have
been seen with CYP P450 3A4 isoenzyme inhibitors, which
tend to increase the plasma levels of sildenafil (Muirhead
et al., 2000).
Sildenafil has been found to be efficacious in ED following
radical prostatectomy (Zagaja et al., 2000; Montorsi et al.,
2004), spinal cord injury (Derry et al., 1998), ED with
diabetes mellitus (Rendell et al., 1999; Hirsh et al., 1999),
ED with chronic renal failure (Chen et al., 2001,),
Parkinson’s disease (Hussain et al., 2001; Zesiewicz et al.,
2000) and in elderly males (Wagner et al., 1998).
A short-term, randomized, double blind study (Seidman et
al., 2001) found sildenafil to be efficacious in patients with
comorbid mild to moderate depressive disorders.
Improvement in ED was also associated with improvement
in depressive symptoms and quality of life. Erectile
dysfunction and associated sexual dysfunction secondary
to antidepressant therapy may occur up to 90% of men
(Rosen & Marin, 2003). Selective serotonin reuptake
inhibitors (SSRIs) and tricyclic antidepressants (TCA) are
amongst the drugs, which cause maximum sexual
dysfunction. Mixed mediators, non-serotonergic
antidepressants that block post-synaptic serotonin type 2
receptors (nefazodone, mitrazapine) or those that primarily
increase dopamine or norepinephrine levels (bupropion)
were thought to be good choices for avoiding antidepressant
induced sexual dysfunction. However, most of these studies
have methodological flaws, which make the claims difficult
to substantiate. Augmentation with these agents to TCAs
or SSRIs has not shown clear evidence of any improvement
in sexual dysfunction. Therefore, few proposed treatment
options apart from avoidance of offending drugs have
proved effective for antidepressant associated sexual
dysfunction. (Labbate et al, 2003).
There are other PDE-5 inhibitors under various stages of
development (Pryor & Redman, 2000) like vardenafil, which
is a highly selective PDE-5 inhibitor. Four randomized,
placebo-controlled, double-blind, multicenter studies have
found it to be effective in ED especially in sexual functioning,
confidence, orgasmic functioning and overall satisfaction
(Keating & Scott, 2004; Crowe & Streetman, 2004;
Kendirci et al, 2004; Porst et al, 2001). Another PDE-5
inhibitor, tadalafil’s clinical trials have shown it to significantly
enhance erectile functioning across a wide range of ED
cases including those with psychogenic, organic and mixed
etiologies (Kloner et al., 2003; Padma-Nathan, 2003).
However, no head to head trials have been undertaken to
compare these newer generation PDE-5 inhibitors with
sildenafil.
ii) Other Oral Erectogenic Agents
One of the earliest drugs used in erectile dysfunction was
trazodone. Trazodone and its active metabolite mCCP, both
have antagonistic effect on 5HT2c receptors and may also
have adrenoceptor antagonistic action (Monsma et al., 1993;
Krege et al., 2000). One of the more recent double-blind,
placebo-controlled, randomized studies in non-organic ED
found trazodone to be more efficacious (Enzlin et al., 2000).
A systematic review and metaanalysis of 6 trials of
trazodone treatment of ED proved that trazodone was more
efficacious than placebo in mixed and psychogenic ED (Fink
et al., 2003).
Yohimbine is an alpha-2-adrenergic blocker. Before
introduction of sildenafil, yohimbine was the most widely
used oral treatment of ED. Two initial studies (Vogt et al.,
1997; Mann et al., 1996) produced inconsistent results, which
prompted American Urologic Association for Erectile
Dysfunction Guidelines (1996) to declare yohimbine as
ineffective in treatment of erectile dysfunction (Padma-
Nathan, 1999; Montague et al., 1996). Later, a meta-
analysis of 7 randomized placebo controlled trials by Ernst
and Pittler (Ernst & Pittler, 1998) found yohimbine to be
superior to placebo. Some researchers now recommend
yohimbine to be a reasonable initial treatment option as its
benefits outweigh its risks (Ernst & Pittler, 1998).
Apomorphine is a dopamine agonist (D1 & D2 receptors)
and its sublingual form (Apo-SL) is a new central initiator
of erection and has been found to be effective in various
types of ED (Dula et al., 2000; Heaton, 1997). When used
in conjunction with a psychosexual counseling strategy, it
can prove as an effective and safe pharmacological therapy
for ED (Costa, 2003). Recent studies show that Apo-SL
has a safe and favourable cardiovascular profile thus making
it a new treatment option for patients with concomitant
diseases including CVS disorders and diabetes mellitus
(Montorsi, 2003).
Oral phentolamine mesylate (Vasomax), which has a faster
onset, readily absorbed drug, is a competitive inhibitor of
alpha-adrenergic receptors. Two double blind placebo-
controlled multicenter trials (Mitka, 1998; Goldstein et al.,
2001) showed better penetration rates and successful
intercourse rates in the test group. It also has the advantage
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of lack of interaction with nitrates and hence has been
suggested as an alternative to treatment of ED with cardiac
illness (Padma-Nathan et al., 2002).
Other oral pharmacological agents like opioid antagonist
Naltrexone (endogenous opioids modulate orgasmic
response and peripheral intensity of sexual arousal and
orgasm)  (van Ahlen et al., 1995; Sathe et al., 2001),
adrenocorticotropin hormone, melanocortin receptor
agonists (Wessells et al 1998; 2000) and antihypertensive
agent losartan (Llisterri et al., 2001) are also under study
for treatment of ED and inhibited sexual desire.
B) Vasoactive Intracavernous Injections
Since early 1980’s, till advent of sildenafil, intracavernous
injections were the mainstay of the treatment of erectile
dysfunction (Brindley, 1983; Virag, 1982).
Phentolamine mesylate, an a-adrenoceptor antagonist acts
via increasing cAMP and decreasing intracellular Ca2+ and
also possibly via nitric oxide synthase (NOS) activation
(Traish et al., 1998). Clinical efficacy and safety of
intracavernosal mesylate has been well documented.
(Anderson, 1995).
Papavarine is a non-selective inhibitor of phosphodiesterase
(PDE) and acts by increasing cAMP thus decreasing
intracellular Ca2+ leading to relaxation of trabecular smooth
muscle. It is used in PIPE test (Papvarine Induced Penile
Erection) to distinguish between psychogenic and organic
ED. However, it has limited efficacy so it is used with other
agents such as phentolamine (bimix) and with phentolamine
and prostaglandin E1 (trimix) (Padma-Nathan, 1999).
Vasoactive Intestinal Peptide (Dinsmore & Alderdice, 1998;
Mac Mohan, 1996) and Forskolin (Mulhall et al., 1997),
which increase cAMP, have been found to be efficacious
in moderate to severe ED resistant to monotherapy and
polypharmacotherapy.
Alprostadil— a synthetic prostaglandin E1 is an adenylate
cyclase activator and is now the drug of choice for
intracavernosal pharmacotherapy (Padma-Nathan, 1995).
Due to its synergistic action, it is often used with
phentolamine and papavarine (Govier et al., 1993). Some
studies demonstrated that patients of erectile dysfunction
preferred trimix (Phentolamine +papavarine + prostaglandin
E1) to sildenafil, regardless of the etiology (Bella & Brock,
2004; Sommer & Engelmann, 2004).
A metaanalysis of 25,000 patients (Steers, 2000) showed
that the advantage of mixing above agents is that lower
doses of drugs are required thus leading onto synergistic
effects with lesser side effects. Prominent side effects are
priapism, pain, corporal fibrosis and scar tissue formation.
Also, being an invasive procedure, many patients find it
inconvenient to inject repeatedly (Linet & Ogrinc, 1996).
Procedural complicacy, bleeding and injury to urethra (Porst,
1995; Purvis et al., 1999) caused higher attrition rates at 1
year follow-up of patients being treated with intracavernosal
vasoactive drugs.
C) Intraurethral Therapy
Medicated urethral system for erection (MUSE), which
contains 500-1000ug of alprostadil, has shown success rates
varying from 43%-69% in efficacy studies (Porst, 1997;
Padma-Nathan et al; 1997). It has advantages that self-
administration had little systemic and local side effects.
D) Topical Therapy
Nitroglycerine, a nitric oxide donor (Cavallini, 1994),
testosterone (Yap & McVary, 2002) and minoxidil ointments
(Cavallini, 1994) have met with only minimal success.
Although, still under investigation. But these agents could
act as another tool in the armamentarium of physicians
treating erectile dysfunction.
II) Premature Ejaculation
Premature (rapid) ejaculation (PME) has been described
as the commonest form of male sexual dysfunction and
implies that a man is unable to exert voluntary control over
the ejaculatory reflex, with the result that once he is sexually
aroused orgasm is achieved rapidly, which leads to
dissatisfaction of patient and his partner. This condition is
most common amongst young adults and men who lack
sexual experience and frequency. In its severe form, it can
lead to secondary erectile dysfunction (Abdel-Hamid,
2004). Premature ejaculation may be primary or secondary
to an underlying disease. Treatment of PME has primarily
focused on behaviour therapy, topical anaesthetic agents,
tricyclic antidepressants and selective serotonin reuptake
inhibitors. However, an approved treatment regime does
not exist.
A study comparing fluoxetine monotherapy with fluoxetine
and local lidocaine ointment application found the latter group
to have longer orgasmic latency (Atan et al., 2000). Three
trials using newer SSRI’s like paroxetine have found it to
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be more efficacious in both long-term as well as on demand
trials (Ludovico et al., 1996; Mac Mohan & Touma, 1999;
Balachandra, 2001). Although, initially it was thought that
different SSRI’s don’t have any advantages over the other
(Murat Bashar et al., 1999) but in a recent systematic review
and meta-analysis of treatment of PME with SSRIs
(Waldinger et al., 2004), it was found that paroxetine
appeared to be more effective in increasing the intra-vaginal
ejaculatory latency time (IELT).
Recently, a number of clinical trials have studied the potential
effectiveness of phosphodiesterase (PDE-5) inhibitor
sildenafil in treatment of PME and have found it to be
benefical either as a single agent (Abdel-Hamid et al., 2001;
Lobik et al., 2002) or in combination with SSRIs like
Paroxetine (Salonia et al., 2002; Chen et al., 2003) and
Sertraline (Lozano & Castane, 2003).
Available data indicate that there is clinical, anatomical,
physiological, pharmacological and genetic evidence to
explain the efficacy of PDE-5 inhibitors in PME. The
rationale for use of PDE-5 inhibitors in treatment of PME
could be due to peripheral and central mechanisms. Possible
peripheral ejaculation retarding capabilities may include
modulation of the contractile response of the vas deference
(VD), seminal vesicles (SV), prostate and urethra; induction
of a state of peripheral analgesia and prolongation of the
total duration of erection (Abdel-Hamid, 2004). Possible
central mechanisms may involve lessening of the central
sympathetic output. Furthermore, there is evidence from
animal studies regarding efficacy of PDE-5 inhibitors in
PME (Abdel-Hamid, 2004). Mice lacking the gene for
endothelial nitric oxide synthase develop a condition similar
to PME (Kriegsfeld et al., 1999). Role of Chinese herbs
like S-S cream, which are used as topical agents have good
efficacy and favorable side effect profile  (Choi et al., 1999;
2000).
Female Sexual Dysfunctions
Female sexual dysfunction is one of the less researched
areas and pathophsiology is not clearly understood. There
are no clear diagnostic criteria for diagnosing these
conditions. Both central nervous system as well as
sympathetic nervous system plays a vital role in both sexual
desire and arousal in females. Nonadranergic noncholinergic
neurotransmitters (NANC) eg. Vasoactive intestinal
polypeptide and nitric oxide are involved in arousal. Female
sex hormones like estrogen has role in smooth muscle
relaxation and enhancement of genital blood flow.
Androgens primarily affect sexual desire, arousal, orgasm
and overall sense of well-being. Like men, in women the
sexual dysfunctions may be caused by organic
(arteriosclerosis, neurological, diabetes mellitus, hormonal
changes and drug induced), psychogenic or mixed etiologies.
In a placebo-controlled study Apomorphine SL has been
found to be effective in both hypoactive sexual desire and
arousal disorders (Caruso et al., 2004). Medical
management of female sexual dysfunction so far is primarily
based on hormone replacement therapy. Several trials have
been conducted using testosterone replacement (Warnock
et al., 1999), yohimbine (Piletz et al., 1998), trazodone,
fenfluramine but with no convincing results. Bupropion
(sustained release) has been found to show moderate
response in non-depressed patients of hyposexual desire
disorders (Segraves et al., 2004). In a single-blind, sequential
order treatment of 3 weeks each of placebo, bupropion-SR
150 mg/day, bupropion 300mg/day, non depressed women
with sexual orgasmic and arousal disorders responded
favourably thus indicating that bupropion-SR may be an
useful agent for treating orgasmic delay and inhibition and
possibly disorders of sexual arousal (Modell et al., 2000).
Conclusion
Erectile dysfunction and premature ejaculation are one of
the most prevalent sexual dysfunctions. The scene in the
treatment of erectile dysfunction and PME has been
revolutionized by the introduction of sildenafil and other
newer PDE-5 inhibitors. The clinical utility of PDE-5
inhibitors in the treatment of PME and ED may be improved
through focusing on the exact PDE isoform expressed in
the human vas deference and seminal vesicles. The various
neurotransmitters like rho-kinases, changes in the central
NO/cGMP signaling pathways should be further studied to
understand exact pathophysiology of erection and
ejaculatory response. The effective and approved treatment
of PME has still not been developed and efforts should be
made to develop such a regime. Other sexual disorders
like female sexual disorders are less understood and less
researched. Greater efforts should be made to understand
female sexual pathophysiology and develop effective
pharmacological treatment for the same.
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